Rosetta Receives Clearance to Sell miRNA Diagnostics in NY State | GenomeWeb

Rosetta Genomics said this week that it has obtained a clinical laboratory permit from the New York State Health Department, clearing the way for the company to market its three commercially available microRNA-based diagnostics in the state.

"We are pleased that these microRNA-based diagnostic products are now available to residents of all 50 US states including New York," Rosetta President and CEO Kenneth Berlin said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.